Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and efficacy of Cetilar®


Clinical Trial Description

After being informed about the study, all patients giving written informed consent will undergo no more than a 1-week screening period to determine eligibility for study entry. Patients that meet inclusion criteria and do not have exclusion criteria will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to Cetilar® cream (about 5 g, twice per day) or placebo cream (about 5 g, twice per day). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06137820
Study type Interventional
Source Pharmanutra S.p.a.
Contact
Status Active, not recruiting
Phase N/A
Start date November 18, 2022
Completion date December 31, 2023